Trust Investment Advisors Sells 241 Shares of Aflac Incorporated (NYSE:AFL)

Trust Investment Advisors trimmed its position in Aflac Incorporated (NYSE:AFL) by 8.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,554 shares of the financial services provider’s stock after selling 241 shares during the period. Trust Investment Advisors’ holdings in Aflac were worth $211,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. BKM Wealth Management LLC bought a new position in shares of Aflac in the 4th quarter valued at $1,558,000. Nordea Investment Management AB raised its position in Aflac by 25.9% during the 4th quarter. Nordea Investment Management AB now owns 1,693,249 shares of the financial services provider’s stock worth $139,676,000 after purchasing an additional 348,400 shares during the last quarter. G&S Capital LLC raised its position in Aflac by 65.1% during the 4th quarter. G&S Capital LLC now owns 31,825 shares of the financial services provider’s stock worth $2,626,000 after purchasing an additional 12,551 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in Aflac by 7.5% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 376,087 shares of the financial services provider’s stock worth $30,786,000 after purchasing an additional 26,338 shares during the last quarter. Finally, Kestra Private Wealth Services LLC raised its position in Aflac by 12.7% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 48,745 shares of the financial services provider’s stock worth $3,741,000 after purchasing an additional 5,477 shares during the last quarter. 67.44% of the stock is currently owned by institutional investors.

Aflac Price Performance

Shares of AFL traded up $0.72 during mid-day trading on Thursday, reaching $80.98. 2,129,906 shares of the stock traded hands, compared to its average volume of 2,238,323. The firm has a fifty day moving average price of $82.06 and a 200 day moving average price of $81.46. The company has a market cap of $46.60 billion, a price-to-earnings ratio of 10.36, a price-to-earnings-growth ratio of 2.21 and a beta of 0.91. The company has a current ratio of 0.06, a quick ratio of 0.06 and a debt-to-equity ratio of 0.33. Aflac Incorporated has a 1 year low of $64.10 and a 1 year high of $86.26.

Aflac (NYSE:AFL) last released its quarterly earnings results on Thursday, February 1st. The financial services provider reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.22). Aflac had a net margin of 24.92% and a return on equity of 17.59%. The firm had revenue of $3.78 billion for the quarter, compared to analysts’ expectations of $4.44 billion. During the same quarter last year, the firm earned $1.29 earnings per share. As a group, equities research analysts predict that Aflac Incorporated will post 6.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on AFL shares. Evercore ISI lowered Aflac from an “in-line” rating to an “underperform” rating and raised their target price for the stock from $76.00 to $78.00 in a research report on Thursday, January 4th. Keefe, Bruyette & Woods lifted their price objective on Aflac from $83.00 to $87.00 and gave the stock a “market perform” rating in a research report on Wednesday, April 10th. Raymond James lifted their price objective on Aflac from $83.00 to $88.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Piper Sandler lifted their price objective on Aflac from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, April 5th. Finally, Morgan Stanley raised their target price on Aflac from $80.00 to $84.00 and gave the company an “equal weight” rating in a research note on Monday. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $82.15.

Insider Buying and Selling

In related news, Director Arthur Reginald Collins sold 3,000 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $79.73, for a total value of $239,190.00. Following the completion of the transaction, the director now directly owns 5,592 shares in the company, valued at $445,850.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Aflac news, Director Arthur Reginald Collins sold 3,000 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $79.73, for a total transaction of $239,190.00. Following the completion of the transaction, the director now owns 5,592 shares of the company’s stock, valued at $445,850.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Masatoshi Koide sold 30,493 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the completion of the transaction, the director now owns 86,090 shares of the company’s stock, valued at $6,879,451.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 46,493 shares of company stock worth $3,765,706. Corporate insiders own 0.90% of the company’s stock.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.